Regn20934

Phase 1

Regeneron

Regn20934 is one of 3 therapeutic programs targeting Overweight or Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight or ObesityRecruiting

Overweight or ObesityPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Overweight or Obesity

#DrugCompanyPhaseTrials

RO7795081

Roche

Phase 1

1 2

Olatorepatide

Regeneron

Phase 2

1 3

Regn20934

Regeneron

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Overweight or Obesity

NCT07594093

Clinical

Trials by Indication[1]

Overweight or Obesity1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity

Recruiting· Regeneron logo

Regeneron·Phase 1·NCT07594093·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regn20934. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Regn20934. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Regeneron

Regn20934

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Overweight or Obesity1 trial

References

Drug Info

Quick Facts

Related News